Navigation Links
Tarsa Therapeutics Presents Positive Efficacy and Safety Data Comparing Its Oral Calcitonin to Nasal Calcitonin and Placebo in Phase III Osteoporosis Treatment Trial
Date:9/19/2011

ood and Drug Administration and to submitting a Marketing Authorization Application to the European Medicines Agency thereafter.  We also are advancing our ongoing Phase Il trial in osteoporosis prevention, an indication for which our oral calcitonin could be especially relevant."

Tarsa's oral calcitonin is also being assessed in a double-blind Phase II study comparing the OSTORA tablet to placebo in postmenopausal women who have low bone mass (osteopenia) and are at increased risk of fracture.  This proof-of-concept study is evaluating the ability of oral calcitonin to prevent osteoporosis and maintain bone mass in this population.  

Tarsa is developing its OSTORA oral calcitonin under a licensing agreement with Unigene Laboratories that provides Tarsa with exclusive development and worldwide commercialization rights to Unigene's oral calcitonin product, with the exception of China.  For more information on Unigene, see www.unigene.com.

The American Society for Bone and Mineral Research 2011 Annual Meeting, the premier scientific meeting discussing the latest concepts and innovations in bone and mineral research, is being held September 16-20, 2011 in San Diego, California.  For more information, visit www.asbmr.org/Meetings/AnnualMeeting.aspx .

"Results of the ORACAL Trial: A Phase 3 Randomized Trial of the Safety and Efficacy of Orally Administered Recombinant Salmon Calcitonin Tablets in Postmenopausal Women with Osteoporosis," Neil Binkley MD, Michael Bolognese MD, James P Gilligan PhD, David S Krause MD.  Presented at the ASBMR 2011 Annual Meeting, Oral Session 23, 2:30pm PDT, September 18, 2011.

*The International Osteoporosis Foundation. Osteoporosis: The Inside Story. Fact sheet. Retrieved August 29, 2011, from

SOURCE Tarsa Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
2. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
3. Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases
4. Echo Therapeutics Receives Registered Trademarks for Symphony® and Prelude®
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
6. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
7. Rare Disease Therapeutics, Inc. Selects Accredo Health Group to Distribute Anascorp® for the Treatment of Centruroides Scorpion Sting Envenomation
8. Silence Therapeutics and InteRNA Technologies Sign Collaboration to Develop Novel microRNA Therapeutics
9. Nile Therapeutics to Present at Rodman & Renshaw Global Investment Conference
10. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
11. Global Sepsis Therapeutics Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Reaching a critical milestone in the ... of Boards of Pharmacy ® (NABP ® ) ... has passed the Internet Corporation for Assigned Names and ... .PHARMACY gTLD by the end of 2013, and will ... and related entities that are located in ...
(Date:5/21/2013)... 21, 2013 Valeant Pharmaceuticals ... ) (TSX: VRX) today announced the ... its 2013 annual meeting of shareholders ... vote for the election of directors ... Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo Melas-Kyriazi237,081,508615,174G. Mason Morfit235,623,2832,073,399J. ...
(Date:5/21/2013)... de 2013 La junta directiva de ... OMNIlife science®, Inc., Enztec, Ltd. y Praxim, SA, han ... Mayer, un ejecutivo ortopédico experimentado, será vicepresidente de ... , un experto refutado en dispositivos médicos, ... unirse a OSI como presidente de la junta, ...
Breaking Medicine Technology:NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3
... N.J., Nov. 9 Unwavering from its pursuit of ... climate, Lutronic, Inc., a leading developer of high quality ... fractional CO2 device priced at under $50,000. , ... to Lutronic,s fractional technology including scanning and stamping operation ...
... (NYSE Amex: KAD ), a leading provider of ... brand, has appointed Stephen Goldsmith to its Board of ... his resignation from the Board. , ... is the Daniel Paul Professor of Government and Director ...
Cached Medicine Technology:Lutronic(R) Unleashes the New MOSAIC CO2 2Arcadia Resources Names Stephen Goldsmith to Board of Directors 2Arcadia Resources Names Stephen Goldsmith to Board of Directors 3
(Date:5/21/2013)... 21, 2013 Patients of Dr. Michael Shenk ... lost teeth due to gum disease and would like permanent ... disease treatment with laser gum surgery. Gum disease ... highest success rate out of all tooth replacement options. ... relatively new procedure cleared by the Food and Drug Administration ...
(Date:5/21/2013)... ContinuCare Home Health, Inc. recently received a ... Disability Services. After completing a four-day review of patient ... Health was found to have no deficiencies to be ... Department of Aging and Disability Services’ mission to provide ... and opportunities that are easily accessed in local ...
(Date:5/21/2013)... SOURCE XT one of the largest, post-approval transcatheter ... at EuroPCR 2013 show good clinical outcomes in routine ... all access approaches, valve sizes and delivery systems. , ... enrolled patients (mean age 81.5 years) undergoing TAVI with ... 17 countries between July 2010 and October 2011. Access ...
(Date:5/21/2013)... The In View series , a ... channels across the country, announces it has posted a ... producers of the series proudly bring audiences across the ... manufacturing industry, health-related companies, medical facilities and more. The ... in all parts of the United States, Canada and ...
(Date:5/21/2013)... Dallas, Texas (PRWEB) May 21, 2013 ... relationships. With the help of Texas Counseling’s Sexuality ... of communication, and the development of healthier habits ... group workshops available for both couples and individuals ... couples enhance their relationships and learn skills to ...
Breaking Medicine News(10 mins):Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2
... Human Vaccine Institute today announced a collaboration and ... enable the rapid development of a vaccine and ... threat such as pandemic influenza. The team, composed ... of the National Institute of Allergy and Infectious ...
... HealthDay Reporter , WEDNESDAY, April 13 (HealthDay News) -- While ... the past few decades, this tragic outcome is still a reality ... a series of studies published online April 14 in The ... in the United States may be obesity, which can raise the ...
... of minor illnesses of astronauts in space may require special ... the space environment. That,s according to Dr. Putcha and ... published online in The AAPS Journal suggest that ... shorter shelf-life than they do on Earth. Pharmaceuticals used ...
... The judgments we make about the intimacy of ... brain chemical serotonin, reports a new study published in ... of serotonin activity had been lowered, rated couples in ... volunteers with normal serotonin activity. The approach involved giving ...
... (HealthDay News) -- Home safety devices greatly reduce the ... a new study. Researchers at Cincinnati Children,s Hospital ... newborns. One set of families had properly installed and ... cabinet locks, electrical outlet covers, smoke alarms, carbon monoxide ...
... By Amanda Gardner HealthDay Reporter , ... highlight the complexities hospitals face in controlling and containing ... to many antibiotics. While one study showed that ... Staphylococcus aureus (MRSA), the other found no ...
Cached Medicine News:Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 2Health News:Duke Human Vaccine Institute signs research agreement to develop pandemic virus vaccines 3Health News:Obesity, Disparities in Care Help Drive U.S. Stillbirths: Studies 2Health News:Obesity, Disparities in Care Help Drive U.S. Stillbirths: Studies 3Health News:Drug potency -- what happens in space? 2Health News:Serotonin: A critical chemical for human intimacy and romance 2Health News:With Safety Devices in Place, Kids' Injuries Decline: Study 2Health News:Studies Highlight Challenge of Controlling Resistant Bacteria in Hospitals 2Health News:Studies Highlight Challenge of Controlling Resistant Bacteria in Hospitals 3
5 mm concave jaws, cross action....
... inserter is the first of its kind. ... through a minimal incision. The special direct-acting ... bag with complete control and predictability. The ... easy around-the-clock, and the instrument has a ...
... SI-30 and SI-40 foldable lenses through incisions as ... clear corneal and corneal scleral tunnels. The inserter ... rounded blades for a secure grasp of a ... a .15 millimeter notch which may be used ...
KR-8000 Supra is capable of obtaining perfectly accurate keratometry and/or refraction measurements through pupils as narrow as 2.0 mm....
Medicine Products: